fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

New analysis of Uplizna for neuromyelitis optica spectrum disorder is published in Neurology Neuroimmunology & Neuroinflammation – Horizon Therapeutics

Written by | 11 May 2021 | Immunology

Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with neuromyelitis optica spectrum disorder (NMOSD). These data are published in the May issue of Neurology Neuroimmunology & Neuroinflammation. Uplizna is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD

A separate analysis of the Phase II/III N-MOmentum trial published in the Annals of Neurology highlights a potential new biomarker of disease activity in NMOSD. Currently there is no blood test that can effectively monitor disease activity, severity of attacks or treatment impact for NMOSD patients. But research has indicated that serum glial fibrillary acidic protein (sGFAP) may be a relevant biomarker for the disease.

See- Marignier R, et al. “Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder”-. Neurol Neuroimmunol Neuroinflamm. 2021;8:e978.https://nn.neurology.org/content/8/3/e978.

See-” Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker”. Ann Neurol. 2021;00:1-16. Available at: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26067.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.